These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 23921085)

  • 41. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
    Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
    Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
    Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
    Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma.
    Cooke M; Kreider-Letterman G; Baker MJ; Zhang S; Sullivan NT; Eruslanov E; Abba MC; Goicoechea SM; García-Mata R; Kazanietz MG
    Cell Rep; 2021 Nov; 37(5):109905. PubMed ID: 34731623
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemotherapy confers a conserved secondary tolerance to EGFR inhibition via AXL-mediated signaling bypass.
    Aldonza MBD; Reyes RDD; Kim YS; Ku J; Barsallo AM; Hong JY; Lee SK; Ryu HS; Park Y; Cho JY; Kim Y
    Sci Rep; 2021 Apr; 11(1):8016. PubMed ID: 33850249
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accelerating AXL targeting for TNBC therapy.
    Khera L; Lev S
    Int J Biochem Cell Biol; 2021 Oct; 139():106057. PubMed ID: 34403827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
    Mahadevan D; Theiss N; Morales C; Stejskal AE; Cooke LS; Zhu M; Kurtzman D; Swart R; Ong E; Qi W
    Oncotarget; 2015 Feb; 6(4):1954-66. PubMed ID: 25557174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AXL as a modulator of sunitinib response in glioblastoma cell lines.
    Martinho O; Zucca LE; Reis RM
    Exp Cell Res; 2015 Mar; 332(1):1-10. PubMed ID: 25637219
    [TBL] [Abstract][Full Text] [Related]  

  • 48. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
    Choi YJ; Kim JH; Rho JK; Kim JS; Choi CM; Kim WS; Son J; Lee JC
    Oncol Rep; 2017 Apr; 37(4):2201-2208. PubMed ID: 28260071
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
    Saxena NK; Taliaferro-Smith L; Knight BB; Merlin D; Anania FA; O'Regan RM; Sharma D
    Cancer Res; 2008 Dec; 68(23):9712-22. PubMed ID: 19047149
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
    Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
    J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
    Jiao Y; Ou W; Meng F; Zhou H; Wang A
    Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
    [TBL] [Abstract][Full Text] [Related]  

  • 52. AXL and acquired resistance to EGFR inhibitors.
    Postel-Vinay S; Ashworth A
    Nat Genet; 2012 Jul; 44(8):835-6. PubMed ID: 22836088
    [No Abstract]   [Full Text] [Related]  

  • 53. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
    Choi YJ; Kim SY; So KS; Baek IJ; Kim WS; Choi SH; Lee JC; Bivona TG; Rho JK; Choi CM
    PLoS One; 2015; 10(3):e0119832. PubMed ID: 25780909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.
    Goyette MA; Duhamel S; Aubert L; Pelletier A; Savage P; Thibault MP; Johnson RM; Carmeliet P; Basik M; Gaboury L; Muller WJ; Park M; Roux PP; Gratton JP; Côté JF
    Cell Rep; 2018 May; 23(5):1476-1490. PubMed ID: 29719259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
    Leconet W; Chentouf M; du Manoir S; Chevalier C; Sirvent A; Aït-Arsa I; Busson M; Jarlier M; Radosevic-Robin N; Theillet C; Chalbos D; Pasquet JM; Pèlegrin A; Larbouret C; Robert B
    Clin Cancer Res; 2017 Jun; 23(11):2806-2816. PubMed ID: 27923843
    [No Abstract]   [Full Text] [Related]  

  • 57. AXL regulates mesothelioma proliferation and invasiveness.
    Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
    Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protein kinase C α is involved in the regulation of AXL receptor tyrosine kinase expression in triple-negative breast cancer cells.
    Yue CH; Liu LC; Kao ES; Lin H; Hsu LS; Hsu CW; Lin YY; Lin YS; Liu JY; Lee CJ
    Mol Med Rep; 2016 Aug; 14(2):1636-42. PubMed ID: 27357025
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Matalkah F; Martin E; Zhao H; Agazie YM
    Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays.
    Gujral TS; Karp RL; Finski A; Chan M; Schwartz PE; MacBeath G; Sorger P
    Oncogene; 2013 Jul; 32(29):3470-6. PubMed ID: 22945653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.